Next-Generation Extracorporeal Blood Treatment System
Legal Citation
Summary of the Inventive Concept
A wearable, implantable, or minimally invasive blood treatment system integrating micro-robotic navigation, artificial intelligence, and blockchain technology to revolutionize extracorporeal blood treatment.
Background and Problem Solved
The original patent's extracorporeal blood treatment apparatus, while effective, has limitations in terms of size, complexity, and data management. The new inventive concept addresses these limitations by proposing a next-generation system that is more compact, efficient, and data-driven.
Detailed Description of the Inventive Concept
The system comprises a wearable, implantable, or minimally invasive blood treatment device, a blood warming device integrated with a micro-robotic navigation system, and an artificial intelligence-powered blood circuit optimization module. The device utilizes a nano-material-based blood filter, a bio-compatible blood warming device, and a wireless power transfer system for powering the device. The system also features a decentralized, blockchain-based data management system for tracking patient treatment data and a machine learning algorithm to predict and prevent blood treatment complications.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious features, including the integration of micro-robotic navigation, artificial intelligence, and blockchain technology, which significantly improve the efficiency, safety, and data management of extracorporeal blood treatment.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include a modular, 3D-printed blood treatment device, a swarm of micro-robots for cleaning and preparing the blood circuit, and a machine learning algorithm to optimize the priming process based on real-time sensor data.
Potential Commercial Applications and Market
The next-generation extracorporeal blood treatment system has significant commercial potential in the medical device industry, particularly in the areas of cardiovascular disease, oncology, and critical care. The system's compact size, efficiency, and data-driven approach make it an attractive solution for hospitals, clinics, and patients worldwide.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61M1/369 |
| A | A61 | A61M1/3623 |
| A | A61 | A61M1/3626 |
| A | A61 | A61M1/3627 |
| A | A61 | A61M1/3643 |
| A | A61 | A61M39/28 |
| A | A61 | A61M2205/3344 |
| A | A61 | A61M2205/36 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device engineering, specifically extracorporeal blood treatment systems, involving complex medical apparatus design, fluid management, and patient treatment technologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer with advanced degree, expertise in medical device design, fluid dynamics, medical instrumentation, and familiarity with emerging medical technologies like micro-robotics and AI-assisted medical systems
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of micro-robotic navigation, AI optimization, and blockchain tracking represents predictable technological extensions of existing extracorporeal blood treatment apparatus design. The core functional elements of blood treatment, warming, and circuit management remain consistent with the source patent, with the PTD merely introducing contemporary technological enhancements. These variations represent standard engineering problem-solving approaches in medical device innovation.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,715 |
|---|---|
| Title | Extracorporeal blood treatment apparatus |
| Assignee(s) | Gambro Lundia AB |